Isomorphic Labs has raised $5 billion in Series C funding to expand its AI drug-design platform and move its experimental medicines closer to human trials. The bet is no longer just on predicting biology, but on using those predictions to develop real treatments.
Greenoaks and Sequoia Capital co-led the November 17 round, with Andreessen Horowitz joining as a new investor and Alphabet committing more capital. All existing investors participated, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
What the $5B Will Build
The new capital will go toward refining Isomorphic’s drug design engine, known as IsoDDE, expanding its medicine pipeline and building infrastructure for development and clinical research. That last part matters: discovering a promising molecule is very different from turning it into an approved treatment.
IsoDDE brings together foundational AI simulation models that operate across multiple therapeutic areas and types of drugs. Isomorphic says the system can explore vast chemical spaces, model complex biological interactions and help scientists design molecules with the properties needed to become viable medicines.
The company is also developing AI agents that reason across difficult biological problems, alongside the simulation models. Its goal is to make drug design a repeatable engineering process rather than a series of disconnected experiments.
The Move Toward Human Trials
Isomorphic says it is seeing positive preclinical results from internal programs in oncology and immunology, as well as from work with partners. Preclinical progress is an important step, but it is not evidence that a medicine is safe or effective in people.
The company has not announced clinical trial results or a specific first-trial start date in this funding release. The next meaningful milestone will be getting its own drug candidates into human studies and showing that AI-informed molecular design can hold up outside the lab.
Investors Back a Longer Timeline
This is the company’s second multibillion-dollar round in six months. It raised $2.1 billion in May 2026, following its first $600 million external financing in March 2025. The scale of the new commitment reflects investor appetite for a longer, capital-intensive effort.
Isomorphic has also disclosed strategic partnerships with Novartis, Lilly and Johnson & Johnson, giving it a route to work on drug programs alongside established pharmaceutical companies while building its own pipeline.
The money buys Isomorphic Labs the capacity to build models, teams and trials at the same time. What it cannot buy is clinical proof. That is the question its next phase must answer.
Get stories like this in your inbox every week. Subscribe to The Week in Perspective.

